epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   230 Trials   230 Trials   3979 News 


«12...3435363738394041424344...5051»
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Clinical, Journal:  Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. (Pubmed Central) -  Mar 8, 2019   
    Pertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer. Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date, Metastases:  Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) -  Mar 1, 2019   
    P2,  N=20, Recruiting, 
    These results are similar to pCR rates seen in trials using HER2-targeted therapy during the taxane phase only of sequential taxane-anthracycline regimens and suggest that we have reached a therapeutic plateau with HER2-targeted therapies combined with chemotherapy in the neoadjuvant setting. Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
  • ||||||||||  Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
    Biomarker, Trial completion date, Trial primary completion date, Metastases:  IMMUN-HER: Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients (clinicaltrials.gov) -  Feb 27, 2019   
    P2,  N=60, Recruiting, 
    Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020 Trial completion date: Jan 2019 --> Nov 2021 | Trial primary completion date: Dec 2018 --> Mar 2019
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Trial completion date, Trial primary completion date, Metastases:  MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) -  Feb 20, 2019   
    P2,  N=400, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020
  • ||||||||||  Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
    Trial completion date:  TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) -  Feb 18, 2019   
    P3,  N=500, Active, not recruiting, 
    Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020 Trial completion date: Dec 2019 --> Apr 2020
  • ||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Enrollment closed, Metastases:  NeoTRIPaPDL1: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (clinicaltrials.gov) -  Feb 15, 2019   
    P3,  N=278, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Aug 2019 Recruiting --> Active, not recruiting
  • ||||||||||  Roferon A (recombinant interferon alfa-2a) / Roche
    Retrospective data, Review, Journal:  Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. (Pubmed Central) -  Dec 14, 2018   
    For NMIBC, several intravesical therapies are associated with decreased risk of bladder cancer recurrence versus TURBT alone. BCG is the only agent associated with decreased progression risk versus TURBT alone, but may be associated with higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms.
  • ||||||||||  azacitidine / Generic mfg.
    Trial completion:  VEOX: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (clinicaltrials.gov) -  Dec 12, 2018   
    P1,  N=12, Completed, 
    BCG is the only agent associated with decreased progression risk versus TURBT alone, but may be associated with higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms. Active, not recruiting --> Completed
  • ||||||||||  Review, Journal:  Predicting and Preventing Anthracycline-Related Cardiotoxicity. (Pubmed Central) -  Nov 29, 2018   
    Studies are currently under way to test risk-reducing strategies. There remains a critical need to identify patients with childhood cancer at diagnosis (i.e., prior to anthracycline exposure) such that noncardiotoxic therapies can be contemplated.
  • ||||||||||  epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Phase classification:  The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer (clinicaltrials.gov) -  Nov 29, 2018   
    P=N/A,  N=50, Not yet recruiting, 
    There remains a critical need to identify patients with childhood cancer at diagnosis (i.e., prior to anthracycline exposure) such that noncardiotoxic therapies can be contemplated. Phase classification: P1 --> P=N/A
  • ||||||||||  epirubicin / Generic mfg.
    Trial completion date, Trial primary completion date:  STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma (clinicaltrials.gov) -  Nov 6, 2018   
    P=N/A,  N=109, Recruiting, 
    Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Aug 2018 --> Nov 2018
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy:  NeoToc: Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer (clinicaltrials.gov) -  Oct 9, 2018   
    P2,  N=80, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> Mar 2019
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  MEMORI: Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction (clinicaltrials.gov) -  Sep 25, 2018   
    P2,  N=75, Active, not recruiting, 
    Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2019 --> Dec 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2018
  • ||||||||||  Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
    Enrollment closed:  TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) -  Sep 25, 2018   
    P3,  N=500, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (clinicaltrials.gov) -  Aug 20, 2018   
    P2,  N=60, Recruiting, 
    Trial completion date: Dec 2020 --> Aug 2020 Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2033 | Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Dec 2027 --> Mar 2028